Stockreport

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HN [Read more]